C4 Therapeutics Inc. (CCCC)
undefined
undefined%
At close: undefined
4.22
-3.76%
After-hours Dec 13, 2024, 05:44 PM EST

C4 Therapeutics Statistics

Share Statistics

C4 Therapeutics has 70.59M shares outstanding. The number of shares has increased by 40.96% in one year.

Shares Outstanding 70.59M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.77%
Owned by Institutions (%) n/a
Shares Floating 56.92M
Failed to Deliver (FTD) Shares 1.71K
FTD / Avg. Volume 0.16%

Short Selling Information

The latest short interest is 5.85M, so 8.29% of the outstanding shares have been sold short.

Short Interest 5.85M
Short % of Shares Out 8.29%
Short % of Float 10.33%
Short Ratio (days to cover) 8.83

Valuation Ratios

The PE ratio is -2.12 and the forward PE ratio is -3.22.

PE Ratio -2.12
Forward PE -3.22
PS Ratio 13.51
Forward PS 12.7
PB Ratio 1.14
P/FCF Ratio -2.58
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

C4 Therapeutics Inc. has an Enterprise Value (EV) of 224.85M.

EV / Earnings -1.7
EV / Sales 10.83
EV / EBITDA -1.84
EV / EBIT -1.62
EV / FCF -2.07

Financial Position

The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.29.

Current Ratio 6.34
Quick Ratio 6.34
Debt / Equity 0.29
Total Debt / Capitalization 22.38
Cash Flow / Debt -1.51
Interest Coverage -101.26

Financial Efficiency

Return on equity (ROE) is -0.54% and return on capital (ROIC) is -44.27%.

Return on Equity (ROE) -0.54%
Return on Assets (ROA) -0.35%
Return on Capital (ROIC) -44.27%
Revenue Per Employee 143.14K
Profits Per Employee -913.74K
Employee Count 145
Asset Turnover 0.06
Inventory Turnover 0

Taxes

Income Tax 1.28M
Effective Tax Rate -0.01

Stock Price Statistics

The stock price has increased by -11.52% in the last 52 weeks. The beta is 3.06, so C4 Therapeutics 's price volatility has been higher than the market average.

Beta 3.06
52-Week Price Change -11.52%
50-Day Moving Average 5.2
200-Day Moving Average 6.17
Relative Strength Index (RSI) 44.76
Average Volume (20 Days) 1.10M

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $20.76M and earned -$132.49M in profits. Earnings per share was $-2.67.

Revenue 20.76M
Gross Profit -96.95M
Operating Income -139.03M
Net Income -132.49M
EBITDA -122.10M
EBIT -139.03M
Earnings Per Share (EPS) -2.67
Full Income Statement

Balance Sheet

The company has $126.59M in cash and $70.98M in debt, giving a net cash position of $55.61M.

Cash & Cash Equivalents 126.59M
Total Debt 70.98M
Net Cash 55.61M
Retained Earnings -528.38M
Total Assets 376.06M
Working Capital 229.94M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$106.84M and capital expenditures -$1.71M, giving a free cash flow of -$108.55M.

Operating Cash Flow -106.84M
Capital Expenditures -1.71M
Free Cash Flow -108.55M
FCF Per Share -2.19
Full Cash Flow Statement

Margins

Gross margin is -467.09%, with operating and profit margins of -669.84% and -638.34%.

Gross Margin -467.09%
Operating Margin -669.84%
Pretax Margin -632.17%
Profit Margin -638.34%
EBITDA Margin -588.28%
EBIT Margin -669.84%
FCF Margin -522.96%

Dividends & Yields

CCCC does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -60.96%
FCF Yield -35.07%
Dividend Details

Analyst Forecast

The average price target for CCCC is $8, which is 82.6% higher than the current price. The consensus rating is "Hold".

Price Target $8
Price Target Difference 82.6%
Analyst Consensus Hold
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score -0.84
Piotroski F-Score 4